Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 20, 2020 - Issue 3
Submit an article Journal homepage
4,713
Views
9
CrossRef citations to date
0
Altmetric
Original Research

Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis

Ben F.M. Wijnena Centre of Economic Evaluation (Trimbos Institute), Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands;b Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The NetherlandsCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7993-1905View further author information
ORCID Icon,
Frederick W. Thielenc Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The NetherlandsView further author information
,
Steef Koningsd Department of Psychiatry, University of Groningen,University Medical Center Groningen, Groningen, The NetherlandsView further author information
,
Talitha Feenstrae Faculty of Medical Sciences, Epidemiology, University Medical Centre Groningen, Groningen, The NetherlandsView further author information
,
Mark Van Der Gaagf Department of Clinical Psychology, VU University, Amsterdam, The Netherlands;g Department of Psychosis Research, Parnassia Psychiatric Institute, Den Haag, The NetherlandsORCID Iconhttps://orcid.org/0000-0002-3525-6415View further author information
ORCID Icon,
Wim Velingd Department of Psychiatry, University of Groningen,University Medical Center Groningen, Groningen, The NetherlandsView further author information
,
Lieuwe De Haanh Department of Psychiatry, Early Psychosis Section, Academic Medical Centre, University of Amsterdam, Amsterdam, The NetherlandsView further author information
,
Helga Isingg Department of Psychosis Research, Parnassia Psychiatric Institute, Den Haag, The NetherlandsView further author information
,
Mickaël Hiligsmanni Department of Health Services Research, Maastricht University, Maastricht, The NetherlandsORCID Iconhttps://orcid.org/0000-0003-4274-9258View further author information
ORCID Icon,
Silvia M.A.A. Eversa Centre of Economic Evaluation (Trimbos Institute), Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands;i Department of Health Services Research, Maastricht University, Maastricht, The NetherlandsORCID Iconhttps://orcid.org/0000-0003-1026-570XView further author information
ORCID Icon,
Filip Smita Centre of Economic Evaluation (Trimbos Institute), Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands;j Department of Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands;k Department of Clinical Psychology, VU University Medical Centre, Amsterdam, The NetherlandsView further author information
&
Joran Lokkerbola Centre of Economic Evaluation (Trimbos Institute), Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands;l Department of Health Care Policy, Harvard Medical School, Boston, MA, USAORCID Iconhttps://orcid.org/0000-0001-9949-5442View further author information
ORCID Icon show all
Pages 269-279 | Received 04 Apr 2019, Accepted 12 Jun 2019, Published online: 20 Jun 2019

Figures & data

Figure 1. Markov model ‘PsyMod’.

Figure 1. Markov model ‘PsyMod’.

Table 1. State dependent yearly transition probabilities, as the mortality rate is age dependent it is not presented in this table.

Table 2. justification of epidemiology parameters.

Figure 2. Ten-year epidemiology resulting from the Markov-model.

Figure 2. Ten-year epidemiology resulting from the Markov-model.

Table 3. costs and utilities associated with each state.

Figure 3. Cost-effectiveness plane (left) and cost-effectiveness acceptability curve (right) of the added value of CBTuhr compared to care as usual.

Figure 3. Cost-effectiveness plane (left) and cost-effectiveness acceptability curve (right) of the added value of CBTuhr compared to care as usual.
Supplemental material

Supplemental Material

Download MS Word (119.5 KB)

Related Research Data

The use of a Cumulative Needs for Care Monitor for individual treatment v. care as usual for patients diagnosed with severe mental illness, a cost-effectiveness analysis from the health care perspective
Source: Cambridge University Press (CUP)
Pharmacogenetic Testing in the Clinical Management of Schizophrenia
Source: Ovid Technologies (Wolters Kluwer Health)
The PACE 400 Study
Source: American Medical Association (AMA)
Economic impact of early intervention in people at high risk of psychosis
Source: Cambridge University Press (CUP)
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
Source: Springer Nature
The economic impact of early intervention in psychosis services for children and adolescents
Source: Wiley-Blackwell
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis
Source: Springer Science and Business Media LLC
Cost-effectiveness of an early intervention service for people with psychosis
Source: Royal College of Psychiatrists
Early intervention in psychosis
Source: Royal College of Psychiatrists
Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis
Source: American Medical Association (AMA)
Economic consequences of alternative medication strategies in first episode non-affective psychosis
Source: Elsevier BV
Predictors of recovery in first episode psychosis: The OPUS cohort at 10year follow-up
Source: Elsevier BV
Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model
Source: Elsevier BV
Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study
Source: SAGE Publications
Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis
Source: Figshare
Schizophrenia in the Netherlands: Continuity of Care with Better Quality of Care for Less Medical Costs
Source: Public Library of Science (PLoS)
A Guide to Establishing Psychosis Services
Source: CRC Press
Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention
Source: Cambridge University Press (CUP)
Prognosis of Brief Psychotic Episodes
Source: American Medical Association (AMA)
Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis
Source: Figshare
Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment
Source: Springer Nature
Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features
Source: Elsevier BV
Cost-effectiveness of treating first-episode psychosis: five-year follow-up results from an Italian early intervention programme
Source: Wiley-Blackwell
Family Burden During Exacerbation of Schizophrenia: Quantification and Determinants of Additional Costs
Source: SAGE Publications
Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis
Source: Informa Healthcare
Preventing a first episode of psychosis: Meta-analysis of randomized controlled prevention trials of 12month and longer-term follow-ups
Source: Elsevier BV
AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
Source: Springer Nature
The effect of five years versus two years of specialised assertive intervention for first episode psychosis - OPUS II: study protocol for a randomized controlled trial
Source: Springer Nature
Cognitive therapy for the prevention of psychosis in people at ultra-high risk
Source: Royal College of Psychiatrists
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
Source: Springer Science and Business Media LLC
Can We Predict Psychosis Outside the Clinical High-Risk State? A Systematic Review of Non-Psychotic Risk Syndromes for Mental Disorders
Source: Oxford University Press (OUP)
Is phase-specific, community-oriented treatment of early psychosis- an economically viable method of improving outcome?
Source: Wiley
Predicting Psychosis
Source: American Medical Association (AMA)
Is Early Intervention in Psychosis Cost-Effective Over the Long Term?
Source: Oxford University Press (OUP)
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain
Source: Elsevier BV
Costs of psychosis in 2010: Findings from the second Australian National Survey of Psychosis
Source: SAGE Publications
A Systematic Review
Source: American Medical Association (AMA)
Is the Differential Mortality Gap Worsening Over Time?
Source: American Medical Association (AMA)
The Half-Cycle Correction Explained: Two Alternative Pedagogical Approaches
Source: SAGE Publications
The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis
Source: Cambridge University Press (CUP)
Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions
Source: SAGE Publications
Diagnostic and Statistical Manual of Mental Disorders
Source: American Psychiatric Association
A Cost-Effectiveness Clinical Decision Analysis Model for Treatment of Schizophrenia
Source: Elsevier BV
Ultra-high-risk paradigm: lessons learnt and new directions
Source: BMJ
Rendeert zorgonderzoek in de ggz?*
Source: Springer Nature
Early detection and intervention in first-episode schizophrenia: a critical review
Source: Wiley-Blackwell

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.